- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Translational Development Acquisition Corp. Ordinary Shares (TDAC)

- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: TDAC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit 1.16% | Avg. Invested days 71 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 219.95M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 10.00 - 10.28 | Updated Date 05/1/2025 |
52 Weeks Range 10.00 - 10.28 | Updated Date 05/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.03 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 220386003 | Price to Sales(TTM) - |
Enterprise Value 220386003 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 17250000 | Shares Floating 3032762 |
Shares Outstanding 17250000 | Shares Floating 3032762 | ||
Percent Insiders - | Percent Institutions 7.54 |
Upturn AI SWOT
Translational Development Acquisition Corp. Ordinary Shares
Company Overview
History and Background
Translational Development Acquisition Corp. is a special purpose acquisition company (SPAC) that was founded in 2021. Its primary purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. As a SPAC, it does not have its own operational history or products before a business combination is completed. Its evolution is tied to its ability to identify and acquire a target company.
Core Business Areas
- SPAC Operations: As a SPAC, its core business area is identifying, negotiating, and completing a business combination with a private operating company. This involves raising capital through an initial public offering (IPO), identifying a suitable acquisition target, and then merging with that target, thereby taking the target company public.
Leadership and Structure
Translational Development Acquisition Corp. is led by a management team typical of a SPAC. This usually includes a CEO, CFO, and a board of directors with experience in finance, mergers and acquisitions, and the relevant industry sectors. The specific individuals and their detailed backgrounds would be found in its SEC filings.
Top Products and Market Share
Key Offerings
- SPAC IPO and Business Combination: The 'product' of a SPAC like Translational Development Acquisition Corp. is its ability to provide a route to public markets for a private company through a business combination. Market share is not applicable in a traditional sense for a SPAC; its success is measured by the successful completion of a merger with a high-value target company. Competitors are other SPACs vying for attractive acquisition targets.
Market Dynamics
Industry Overview
The SPAC industry experienced significant growth and subsequent contraction. SPACs offer a faster and sometimes more flexible alternative to traditional IPOs for companies seeking to go public. However, regulatory scrutiny and market volatility have impacted the industry.
Positioning
Translational Development Acquisition Corp.'s positioning is that of a financial vehicle seeking a target. Its competitive advantage lies in its management team's ability to identify promising companies and execute a successful merger. It competes with numerous other SPACs for viable acquisition targets and with traditional IPO routes.
Total Addressable Market (TAM)
The TAM for SPACs is the total value of private companies seeking to go public. While difficult to quantify precisely, it represents a significant portion of the global private equity and venture capital landscape. Translational Development Acquisition Corp. is positioned to target companies within specific sectors, as often indicated in its IPO prospectus, aiming to capture a portion of this TAM through its business combination.
Upturn SWOT Analysis
Strengths
- Experienced management team (typical for SPACs)
- Access to public capital markets for a target company
- Flexibility in deal structure for business combinations
Weaknesses
- Lack of operational history and revenue before a business combination
- Dependence on identifying and successfully merging with a suitable target
- Short time frame to complete a business combination before liquidation
Opportunities
- Identifying undervalued private companies seeking public listing
- Capitalizing on favorable market conditions for IPOs
- Targeting specific growth sectors with high potential
Threats
- Increased regulatory scrutiny of SPACs
- Market volatility and economic downturns affecting target valuations
- Competition from other SPACs and traditional IPOs
- Failure to identify a suitable target within the mandated timeframe
Competitors and Market Share
Key Competitors
- Other SPACs seeking business combinations
- Companies pursuing traditional IPOs
Competitive Landscape
Translational Development Acquisition Corp. competes with hundreds of other SPACs for attractive acquisition targets. Its advantages lie in the expertise of its management team and its ability to structure a compelling deal. Disadvantages include the time constraint and the intense competition in the SPAC market.
Growth Trajectory and Initiatives
Historical Growth: Not applicable in the traditional sense as it is a SPAC. Its 'growth' is defined by its ability to successfully complete a business combination.
Future Projections: Future projections are entirely dependent on the target company identified for the business combination. Analyst estimates would focus on the growth prospects of that target company post-merger.
Recent Initiatives: The primary recent initiative for any SPAC is the ongoing search for and negotiation with a potential business combination target.
Summary
Translational Development Acquisition Corp. is a special purpose acquisition company (SPAC) focused on finding a target for a business combination. Its strength lies in its potential to take a private company public efficiently. However, it faces significant risks due to the competitive SPAC market, regulatory scrutiny, and the inherent uncertainty of identifying and completing a successful merger within its timeframe. Its future success and financial performance are entirely contingent on the outcome of its business combination efforts.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., S-1, 10-K, 8-K)
- Financial news and data providers (e.g., Bloomberg, Refinitiv, Yahoo Finance)
- Industry analysis reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. SPACs are high-risk investments, and investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Information about SPACs can change rapidly, especially regarding potential business combinations. This JSON output reflects the state of the company as a SPAC, prior to any potential business combination.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Translational Development Acquisition Corp. Ordinary Shares
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2025-02-13 | Chairman of the Board & CEO Mr. Michael M. B. Hoffman J.D. | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | |
Full time employees - | |||
Translational Development Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
Home 

